MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Data analysis identified differently expressed genes in MDS and the cluster of four genes (ERCC1, FLT1, NME4 and PCNA) whose expression was correlated with MDS subtypes.
|
18604718 |
2008 |
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Data analysis identified differently expressed genes in MDS and the cluster of four genes (ERCC1, FLT1, NME4 and PCNA) whose expression was correlated with MDS subtypes.
|
18604718 |
2008 |
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exposing the cells to 1600 µg/ml of the water fraction resulted in several gene changes that may also be beneficial in the treatment of colon cancer: NME4, TEK, and THBS1.
|
23553997 |
2014 |
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Exposing the cells to 1600 µg/ml of the water fraction resulted in several gene changes that may also be beneficial in the treatment of colon cancer: NME4, TEK, and THBS1.
|
23553997 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, lentivirus‑mediated knockdown vector infection, cell proliferation, cell cycle, apoptosis, colony formation and MTT assays were conducted to explore the effect of NME4 on NSCLC in vitro.
|
31257488 |
2019 |
Childhood Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome.
|
18604718 |
2008 |
Adult Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome.
|
18604718 |
2008 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In contrast, by immunohistochemical analysis, nm23-H4 and -H6 overexpression correlated with the intestinal tumour type in gastric cancer tissues, whereas no increased immunoreactivity for the three nm23 proteins was noted in the diffuse type tumour specimens.
|
15726650 |
2005 |
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In order to investigate the role of NME4 in NSCLC, the present study detected the expression of the NME4 gene in the Cancer Genome Atlas database, and in BEAS‑2B, NCI‑H1299 and A549 cell lines.
|
31257488 |
2019 |
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In order to investigate the role of NME4 in NSCLC, the present study detected the expression of the NME4 gene in the Cancer Genome Atlas database, and in BEAS‑2B, NCI‑H1299 and A549 cell lines.
|
31257488 |
2019 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we show that NDPK-D knockdown induces apoptosis in neuroblastoma cells as well as in mouse cortex, suggesting that NDPK-D is required for neuronal survival.
|
26426123 |
2015 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we show that NDPK-D knockdown induces apoptosis in neuroblastoma cells as well as in mouse cortex, suggesting that NDPK-D is required for neuronal survival.
|
26426123 |
2015 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we show that NDPK-D knockdown induces apoptosis in neuroblastoma cells as well as in mouse cortex, suggesting that NDPK-D is required for neuronal survival.
|
26426123 |
2015 |
Malignant neoplasm of mouth
|
0.010 |
Biomarker
|
group |
BEFREE |
OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway.
|
25233933 |
2014 |
Lip and Oral Cavity Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathway.
|
25233933 |
2014 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The nm23-H4 transcript levels did not correlate with tumour stage, grade of differentiation or lymph node involvement.
|
11724361 |
2001 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The present results suggested that NME4 may serve as a novel tumor promoter, capable of enhancing NSCLC progression by overcoming cell cycle arrest and promoting proliferation.
|
31257488 |
2019 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To determine whether nm23-H4 could have a function in tumour progression like nm23-H1 or nm23-H2, we analysed nm23-H4 expression in 18 renal tumours and 42 colorectal carcinomas obtained from patients who underwent curative resection.
|
11724361 |
2001 |
Kidney Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To determine whether nm23-H4 could have a function in tumour progression like nm23-H1 or nm23-H2, we analysed nm23-H4 expression in 18 renal tumours and 42 colorectal carcinomas obtained from patients who underwent curative resection.
|
11724361 |
2001 |
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
While the increase was only moderate in renal cell carcinoma, a strong overexpression of nm23-H4 was noted in most colorectal carcinomas, possibly indicating a role of this gene in tumour genesis.
|
11724361 |
2001 |